Satellos Bioscience Inc. (TO:MSCL) — Market Cap & Net Worth
Market Cap & Net Worth: Satellos Bioscience Inc. (MSCL)
Satellos Bioscience Inc. (TO:MSCL) has a market capitalization of $158.46 Million (CA$219.06 Million) as of May 4, 2026. Listed on the TO stock exchange, this Canada-based company holds position #17417 globally and #556 in its home market, demonstrating a 11.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Satellos Bioscience Inc.'s stock price CA$10.62 by its total outstanding shares 20626922 (20.63 Million). Analyse MSCL cash flow conversion to see how efficiently the company converts income to cash.
Satellos Bioscience Inc. Market Cap History: 2015 to 2026
Satellos Bioscience Inc.'s market capitalization history from 2015 to 2026. Data shows growth from $11.94 Million to $158.46 Million (21.20% CAGR).
Satellos Bioscience Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Satellos Bioscience Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
954.96x
Satellos Bioscience Inc.'s market cap is 954.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $23.87 Million | $25.00K | -$1.99 Million | 954.96x | N/A |
Competitor Companies of MSCL by Market Capitalization
Companies near Satellos Bioscience Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Satellos Bioscience Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Satellos Bioscience Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Satellos Bioscience Inc.'s market cap moved from $11.94 Million to $ 158.46 Million, with a yearly change of 21.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$158.46 Million | +1509.09% |
| 2025 | CA$9.85 Million | -20.48% |
| 2024 | CA$12.38 Million | +93.02% |
| 2023 | CA$6.42 Million | +95.45% |
| 2022 | CA$3.28 Million | -78.00% |
| 2021 | CA$14.92 Million | -16.67% |
| 2020 | CA$17.91 Million | -25.00% |
| 2019 | CA$23.87 Million | +60.00% |
| 2018 | CA$14.92 Million | +25.00% |
| 2017 | CA$11.94 Million | -20.00% |
| 2016 | CA$14.92 Million | +25.00% |
| 2015 | CA$11.94 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Satellos Bioscience Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $158.46 Million USD |
| MoneyControl | $158.46 Million USD |
| MarketWatch | $158.46 Million USD |
| marketcap.company | $158.46 Million USD |
| Reuters | $158.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy di… Read more